Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01285_DB06717_nanopub.RAR1b013-E8bLAcl9Il_VP54yVAYnZBygulpO1rjBajQE#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01285_DB06717 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01285_DB06717 label "DDI between Corticotropin and Fosaprepitant - Fosaprepitant may increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. The manufacturer of fosaprepitant states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone.1 Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen. Monitor for increased effects of systemic corticosteroids when coadmininistered with fosaprepitant or aprepitant. [drugbank_resource:DB01285_DB06717]" assertion.
- drugbank_resource:DB01285_DB06717 identifier "drugbank_resource:DB01285_DB06717" assertion.
- drugbank_resource:DB01285_DB06717 title "DDI between Corticotropin and Fosaprepitant - Fosaprepitant may increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. The manufacturer of fosaprepitant states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone.1 Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen. Monitor for increased effects of systemic corticosteroids when coadmininistered with fosaprepitant or aprepitant." assertion.
- drugbank:DB01285 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01285_DB06717 assertion.
- drugbank:DB06717 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01285_DB06717 assertion.